Dominique Hubert1, Raphaël Chiron2, Boubou Camara3, Dominique Grenet4, Anne Prévotat5, Laurence Bassinet6, Stéphane Dominique7, Gilles Rault8, Julie Macey9, Isabelle Honoré10, Reem Kanaan10, Sylvie Leroy11, Nadine Desmazes Dufeu12, Pierre-Régis Burgel10. 1. Pulmonary Department and Adult CF Centre, Cochin Hospital, AP-HP, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France. Electronic address: dominique.hubert@aphp.fr. 2. Pulmonary Department, Arnaud de Villeneuve Hospital, Montpellier, France. 3. Pulmonary Department, University Hospital Grenoble Alpes, Grenoble, France. 4. Adult CF and Lung Transplantation Centre, Foch Hospital, Suresnes, France. 5. Pulmonary Department and Adult CF Centre, Lille University Hospital, Lille, France. 6. Pulmonary Department, Centre Intercommunal de Créteil, Créteil, France. 7. Pulmonary Department, Charles Nicolle Hospital, Rouen University Hospital, Rouen, France. 8. CF centre, Centre héliomarin de Perharidy, Roscoff, France. 9. Pulmonary Department and adult CF centre, Bordeaux University Hospital, Bordeaux, France. 10. Pulmonary Department and Adult CF Centre, Cochin Hospital, AP-HP, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France. 11. FHU OncoAge, Côte d'Azur University, Nice, France. 12. Adult CF Centre, CHU Nord, AP-HM, Marseille, France.
Abstract
OBJECTIVE: To investigate the short-term adverse events and effectiveness of lumacaftor/ivacaftor combination treatment in adults with cystic fibrosis (CF) and severe lung disease in a real life setting. METHODS: A multicentre observational study investigated adverse events, treatment discontinuation, FEV1 and body mass index (BMI) one month and three months after lumacaftor/ivacaftor initiation in adults with CF and FEV1 below 40% predicted. RESULTS: Respiratory adverse events (AEs) were reported by 27 of 53 subjects (51%) and 16 (30%) discontinued treatment. The mean absolute change in FEV1 was +2.06% after one month of treatment (P=0.086) and +3.19% after 3 months (P=0.009). BMI was unchanged. CONCLUSIONS: Treatment with lumacaftor/ivacaftor in patients with CF and severe lung disease was discontinued more frequently than reported in clinical trials, due to respiratory AEs. Nevertheless, the patients who continued treatment had an increase in lung function comparable to what was observed in pivotal trials.
OBJECTIVE: To investigate the short-term adverse events and effectiveness of lumacaftor/ivacaftor combination treatment in adults with cystic fibrosis (CF) and severe lung disease in a real life setting. METHODS: A multicentre observational study investigated adverse events, treatment discontinuation, FEV1 and body mass index (BMI) one month and three months after lumacaftor/ivacaftor initiation in adults with CF and FEV1 below 40% predicted. RESULTS: Respiratory adverse events (AEs) were reported by 27 of 53 subjects (51%) and 16 (30%) discontinued treatment. The mean absolute change in FEV1 was +2.06% after one month of treatment (P=0.086) and +3.19% after 3 months (P=0.009). BMI was unchanged. CONCLUSIONS: Treatment with lumacaftor/ivacaftor in patients with CF and severe lung disease was discontinued more frequently than reported in clinical trials, due to respiratory AEs. Nevertheless, the patients who continued treatment had an increase in lung function comparable to what was observed in pivotal trials.
Authors: Benjamin T Kopp; James Fitch; Lisa Jaramillo; Chandra L Shrestha; Frank Robledo-Avila; Shuzhong Zhang; Sabrina Palacios; Fred Woodley; Don Hayes; Santiago Partida-Sanchez; Octavio Ramilo; Peter White; Asuncion Mejias Journal: J Cyst Fibros Date: 2019-08-29 Impact factor: 5.482
Authors: Scott H Donaldson; Joseph M Pilewski; Matthias Griese; Jon Cooke; Lakshmi Viswanathan; Elizabeth Tullis; Jane C Davies; Julie A Lekstrom-Himes; Linda T Wang Journal: Am J Respir Crit Care Med Date: 2018-01-15 Impact factor: 21.405
Authors: Ana M Matos; Andreia Gomes-Duarte; Márcia Faria; Patrícia Barros; Peter Jordan; Margarida D Amaral; Paulo Matos Journal: Sci Rep Date: 2018-08-29 Impact factor: 4.379
Authors: Scott D Sagel; Umer Khan; Sonya L Heltshe; John P Clancy; Drucy Borowitz; Daniel Gelfond; Scott H Donaldson; Antoinette Moran; Felix Ratjen; Jill M VanDalfsen; Steven M Rowe Journal: Ann Am Thorac Soc Date: 2021-01
Authors: Michelle Shaw; Umer Khan; John P Clancy; Scott H Donaldson; Scott D Sagel; Steven M Rowe; Felix Ratjen Journal: J Cyst Fibros Date: 2020-06-06 Impact factor: 5.527